Nondepolarizing neuromuscular blocking agent
Following IV administration of 0.45 or 0.6 mg/kg in adults, neuromuscular blockade is clinically sufficient in about 1.3 (range 0.8–6.2) or 1 (range: 0.4–6) minute, respectively, and is maximal in <4 or <3 minutes, respectively
Good to excellent conditions for rapid sequence intubation result in <2 minutes following dose of 0.6–1.2 mg/kg in appropriately premedicated and adequately anesthetized patients.
Known hypersensitivity to rocuronium bromide or any ingredient in the formulation.
Potential for severely compromised respiratory function and respiratory paralysis. Should be used only by individuals experienced in the use of neuromuscular blocking agents and in the maintenance of an adequate airway and respiratory support.
Administer Rocuronium only after patient has recovered from succinylcholine-induced neuromuscular blockade.
Increased neuromuscular blockade.
Use with caution; reduce rocuronium dosage if necessary.
Change in duration of, or recovery from, neuromuscular blockade unlikely.
Skeletal muscle weakness
0.6–1.2 mg/kg for rapid sequence intubation in appropriately pre-medicated and adequately anesthetized patients.
Children 3 months to 14 years of age: 0.6 mg/kg